Androgen receptor ligands: Agonists and antagonists

Folake A. Orafidiya; Amy E. Monaghan; Iain J. McEwan

doi:10.1016/B978-0-12-801238-3.64586-5

Androgen receptor ligands: Agonists and antagonists

Folake A. Orafidiya, Amy E. Monaghan, Iain J. McEwan

Medical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Citation (Scopus)

Abstract

The androgen receptor is a key regulator of physiological development in utero and tissue homeostasis in adult men and woman. The activity of the receptor is tightly regulated by the binding of the natural steroid hormone agonists, testosterone and dihydrotestosterone. Activation of the receptor leads to dimerization, nuclear translocation and activation of target genes. Clinically, synthetic agonists are used to treat conditions of hormone insufficiency. Conversely conditions arising from androgen excess or a dependence upon the androgen receptor can be treated with antagonists to blunt the response to natural hormones.

Original language	English
Title of host publication	Encyclopedia of Reproduction
Publisher	Elsevier
Pages	234-241
Number of pages	8
ISBN (Electronic)	9780128151457
DOIs	https://doi.org/10.1016/B978-0-12-801238-3.64586-5
Publication status	Published - 30 Jul 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc. All rights reserved.

Keywords

Androgenic steroids
Bicalutamide
Dihydrotestosterone
Enzalutamide
Hypogonadism
Ligand binding domain
Prostate cancer
SARD
SARM
Testosterone

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-801238-3.64586-5

Cite this

@inbook{174e9b0214c040f1853717ca9e3f147b,

title = "Androgen receptor ligands: Agonists and antagonists",

abstract = "The androgen receptor is a key regulator of physiological development in utero and tissue homeostasis in adult men and woman. The activity of the receptor is tightly regulated by the binding of the natural steroid hormone agonists, testosterone and dihydrotestosterone. Activation of the receptor leads to dimerization, nuclear translocation and activation of target genes. Clinically, synthetic agonists are used to treat conditions of hormone insufficiency. Conversely conditions arising from androgen excess or a dependence upon the androgen receptor can be treated with antagonists to blunt the response to natural hormones.",

keywords = "Androgenic steroids, Bicalutamide, Dihydrotestosterone, Enzalutamide, Hypogonadism, Ligand binding domain, Prostate cancer, SARD, SARM, Testosterone",

author = "Orafidiya, {Folake A.} and Monaghan, {Amy E.} and McEwan, {Iain J.}",

year = "2018",

month = jul,

day = "30",

doi = "10.1016/B978-0-12-801238-3.64586-5",

language = "English",

pages = "234--241",

booktitle = "Encyclopedia of Reproduction",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - Androgen receptor ligands

T2 - Agonists and antagonists

AU - Orafidiya, Folake A.

AU - Monaghan, Amy E.

AU - McEwan, Iain J.

PY - 2018/7/30

Y1 - 2018/7/30

N2 - The androgen receptor is a key regulator of physiological development in utero and tissue homeostasis in adult men and woman. The activity of the receptor is tightly regulated by the binding of the natural steroid hormone agonists, testosterone and dihydrotestosterone. Activation of the receptor leads to dimerization, nuclear translocation and activation of target genes. Clinically, synthetic agonists are used to treat conditions of hormone insufficiency. Conversely conditions arising from androgen excess or a dependence upon the androgen receptor can be treated with antagonists to blunt the response to natural hormones.

AB - The androgen receptor is a key regulator of physiological development in utero and tissue homeostasis in adult men and woman. The activity of the receptor is tightly regulated by the binding of the natural steroid hormone agonists, testosterone and dihydrotestosterone. Activation of the receptor leads to dimerization, nuclear translocation and activation of target genes. Clinically, synthetic agonists are used to treat conditions of hormone insufficiency. Conversely conditions arising from androgen excess or a dependence upon the androgen receptor can be treated with antagonists to blunt the response to natural hormones.

KW - Androgenic steroids

KW - Bicalutamide

KW - Dihydrotestosterone

KW - Enzalutamide

KW - Hypogonadism

KW - Ligand binding domain

KW - Prostate cancer

KW - SARD

KW - SARM

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=85079263711&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801238-3.64586-5

DO - 10.1016/B978-0-12-801238-3.64586-5

M3 - Chapter

AN - SCOPUS:85079263711

SP - 234

EP - 241

BT - Encyclopedia of Reproduction

PB - Elsevier

ER -

Androgen receptor ligands: Agonists and antagonists

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this